期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细菌对氟喹诺酮类药物耐药机制的研究进展 被引量：4

在线阅读 下载PDF
导出
摘要 喹诺酮类药物是一类由萘啶酸发展起来的合成抗菌药,其中氟喹诺酮类药物于20世纪80年代起陆续上市,属于第三代喹诺酮类药物,具有抗菌谱广、抗菌活性高、组织穿透性强等特点且可单药使用。
作者 方可华 于锋英
机构地区 山东省滨州市惠民县人民医院内科 河北北方学院药理系
出处 《上海医药》 CAS 2011年第5期227-228,共2页 Shanghai Medical & Pharmaceutical Journal
关键词 氟喹诺酮类药物 耐药机制 第三代喹诺酮类药物 细菌 合成抗菌药 组织穿透性 革兰阳性菌 抗菌谱广
分类号 R978.19 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1Giraud E,Baucheron S,Cloeckaert A.Resistance to fluoroquinolones in Salmonella:Emerging mechanisms and resistance prevention strategies[J].Microbes Infection,2006,8(7):1937-1944.
  • 2Hop Kins KL,Davies RH,Threlfall EJ.Mechanisms of quinolone resistance in Escherichia cob and Salmonella:Rrecent developments[J].Int J Antimicrob Agents,2005,25(5):358-373.
  • 3Bebear CM,Charrion A,Bore JM,et al.Cloning and nucleotide sequences of the of the topisometase Ⅳ parC and pare genes of Myeoplasma bominis[J].Antimicrob Agents Chemother,1998,42(8):2024-2031.
  • 4王辉.第2讲 从细菌耐药机制及其耐药现状来看新氟喹诺酮类药物的优势[J].中国实用内科杂志,2005,25(9):861-862. 被引量：9
  • 5Hooper DC.New uses for new and old quinolones and the challenge of resistance[J].Clin Infect Dis,2000,30(2):243-254.
  • 6Piddock LJ.Mechanisms of fluoroquinolone resistance:An update 1994-1998[J].Drugs,1999,49(Suppl 2):29-32.
  • 7Kang SG,Lee DY,Shin ST,et al.Change in patterns of antimicrobiol susceptibility and class 1 integrons[J].J Veterinary Sci,2005,6(3):201-205.
  • 8Gazew H,Abdouslam N,Hawkey PM,et al.Incidence of class 1 integrons in squatemary ammonium compound polluted environment[J].Antimicrnb Agents Chemother,2005,49(5):1802-1807.
  • 9Jonesm ME,Peters E,Weersink AM,et al.Widesp read occurrenceof integrons causing multiple antibiotic resistance in bacteria[J].Lancet,1997,349(9067):1742-1743.
  • 10杜艳,陈玲玲,邵天波,陈端.克雷伯菌临床菌株中1类整合子相关基因的分析[J].昆明医学院学报,2005,26(1):17-19. 被引量：13

二级参考文献56

  • 1吴礼襄,萧正伦,黎毅敏.MRSA呼吸系统医院感染的分子流行病学调查[J].中华医院感染学杂志,2004,14(4):453-457. 被引量：76
  • 2王睿,裴斐,赵铁梅,朱曼,方翼,柴栋,郑专杰,张永青.莫西沙星等13种抗菌药物对呼吸道常见感染致病菌体外抗菌活性的研究[J].中华检验医学杂志,2004,27(11):739-746. 被引量：34
  • 3马越,李景云,姚蕾,张力,胡昌勤,金少鸿.1999-2003年广东和辽宁地区大肠埃希菌和肺炎克雷伯菌临床分离株耐药性比较分析[J].临床药物治疗杂志,2005,3(2):46-52. 被引量：6
  • 4National Committee ibr Clinical Laboratory Standard. Performance standards for antimicrobial susceptibility testing[M]. Fourteenth informational Supplement,2004.
  • 5Valdezate S, Vindel A, Echeita A, et al. Topiosomerase Ⅱ and Ⅳ quinolone resistance - determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility[J]. Antimicrob Agents Chemother, 2002,46: 665.
  • 6Hooper DC. Becterial topiosomerase, anti- topoiserases and anti-topoiserases resistance[J]. Clin Infect Dis, 1998,27(supp Ⅱ):S54.
  • 7Yoshida H, Bogaki M, Nakamura M et al. Quinolone resistance- determining region in the DNA gyrase gyrA gene of Eacherichia coli[J].Antimicrob Agents Chemother, 1990,34:1271.
  • 8Schneiders T, Arnyes SG, Levy SB. Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore[J]. Antimicrob Agents Chemother,2003,47:2831.
  • 9Deguchi T, Kawamura T, Yasuda M, et al. In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urimary tract infections [J]. Antimicrob Agents Chemother, 1997,41: 1609.
  • 10Brisse S, D Milatovic, A C Fluit, et al. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin and trovafloxacin against Klebsiella pneumoniae, Klebsiella oaytoca,Enterobacter cloacae and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins [J]. Antimicrob Agents Chemother, 1999,43: 2051.

共引文献53

同被引文献36

  • 1程龙飞,陈红梅,施少华,傅光华,万春和,傅秋玲,黄瑜,林建生.鸭疫里默氏菌的血清型及药物敏感性分析[J].中国动物传染病学报,2013,21(4):23-28. 被引量：38
  • 2VALDEZATE S, VINDEL A, ECHEITA A, et al. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility [J]. Antimicrob Agents Cbemotber, 2002, 46 (3) : 665-671.
  • 3DIJKSHOORN L, NEMEC A, SEIFERT H. An increasing threat in hospitals : multidrug-resistant Acinetobacter baumannii [J]. Nat Rev Microbiol, 2007, 5 (12): 939-951.
  • 4SCHUMACHER A, TRITTLER R, BOHNERT JA, et al. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes, role of enhanced efflux pump activity and inactivation [ J ]. J Antimicrob Chemother, 2007, 59 (6) : 1261-1264.
  • 5尹文君.多重耐药鲍曼不动杆菌主动外排系统耐药基因的研究[D].衡阳:南华大学,2012.
  • 6Gao Q,Zheng HB, Luo D, et al. Facile synthesis of magnetic one- dimensional polyaniline and its application in magnetic solid phase extraction for fluoroquinolones in honey samples [ J ]. Anal Chim Acta,2012 ,720 :57-62.
  • 7Hof H, Fahr A, Holfelder M, et al. Severe pneumococcal infections in the elderly-preventable by vaccination [ J ]. Z Gerontol Geriatr, 2013,46 (2) : 160-166.
  • 8Abbasi S, Imtiaz A, Usman J, et al. Evaluation of the current trend of nalidixic acid susceptibility in typhaidal Salmonellae; a marker of therapeutic failure for the fluoroquinolones[ J]. Iran J Miembiol, 2011,3(2) :80-83.
  • 9Castanheira M,I)eshpande LM, Jones RN, et al. Evaluation of quino- lone resistance-determining region mutations and effiux pump expres- sion in Neisseria meningitidis resistant to fluoroquinolones [ J ]. Diagn Microbiol Infect Dis,2012,72 ( 3 ) : 263-266.
  • 10Rice LB. Mechanisms of Resistance and Clinical Relevance of Resistance to [3-Lactams, Glycopeptides, and Fluoroquinolones [ J]. Mayo Clin Proc,2012,87 (2) : 198-208.

引证文献4

二级引证文献10

上海医药
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部